Report Detail
Global PD-L1 Biomarker Testing Market 2023 by Company, Regions, Type and Application, Forecast to 2029
- RnM4512921 |
- 18 February, 2023 |
- Global |
- 86 Pages |
- GIR (Global Info Research) |
- Other
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
According to our (Global Info Research) latest study, the global PD-L1 Biomarker Testing market size was valued at USD 1513.1 million in 2022 and is forecast to a readjusted size of USD 4101.9 million by 2029 with a CAGR of 15.3% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.
PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.
North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.
This report is a detailed and comprehensive analysis for global PD-L1 Biomarker Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global PD-L1 Biomarker Testing market size and forecasts, in consumption value ($ Million), 2018-2029
Global PD-L1 Biomarker Testing market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global PD-L1 Biomarker Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global PD-L1 Biomarker Testing market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PD-L1 Biomarker Testing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PD-L1 Biomarker Testing market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Agilent Technologies, Eli Lilly, AstraZeneca, Roche and Bristol-Myers Squibb, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
PD-L1 Biomarker Testing market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
PD-L1 IHC 22C3 Assay
PD-L1 IHC 28-8 Assay
PD-L1 (SP142) Assay
PD-L1 (SP263) Assay
Market segment by Application
Hospital
Diagnostic Center
Others
Market segment by players, this report covers
Agilent Technologies
Eli Lilly
AstraZeneca
Roche
Bristol-Myers Squibb
Merck
Pfizer
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe PD-L1 Biomarker Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of PD-L1 Biomarker Testing, with revenue, gross margin and global market share of PD-L1 Biomarker Testing from 2018 to 2023.
Chapter 3, the PD-L1 Biomarker Testing competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and PD-L1 Biomarker Testing market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of PD-L1 Biomarker Testing.
Chapter 13, to describe PD-L1 Biomarker Testing research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope of PD-L1 Biomarker Testing
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of PD-L1 Biomarker Testing by Type
- 1.3.1 Overview: Global PD-L1 Biomarker Testing Market Size by Type: 2018 Versus 2022 Versus 2029
- 1.3.2 Global PD-L1 Biomarker Testing Consumption Value Market Share by Type in 2022
- 1.3.3 PD-L1 IHC 22C3 Assay
- 1.3.4 PD-L1 IHC 28-8 Assay
- 1.3.5 PD-L1 (SP142) Assay
- 1.3.6 PD-L1 (SP263) Assay
- 1.4 Global PD-L1 Biomarker Testing Market by Application
- 1.4.1 Overview: Global PD-L1 Biomarker Testing Market Size by Application: 2018 Versus 2022 Versus 2029
- 1.4.2 Hospital
- 1.4.3 Diagnostic Center
- 1.4.4 Others
- 1.5 Global PD-L1 Biomarker Testing Market Size & Forecast
- 1.6 Global PD-L1 Biomarker Testing Market Size and Forecast by Region
- 1.6.1 Global PD-L1 Biomarker Testing Market Size by Region: 2018 VS 2022 VS 2029
- 1.6.2 Global PD-L1 Biomarker Testing Market Size by Region, (2018-2029)
- 1.6.3 North America PD-L1 Biomarker Testing Market Size and Prospect (2018-2029)
- 1.6.4 Europe PD-L1 Biomarker Testing Market Size and Prospect (2018-2029)
- 1.6.5 Asia-Pacific PD-L1 Biomarker Testing Market Size and Prospect (2018-2029)
- 1.6.6 South America PD-L1 Biomarker Testing Market Size and Prospect (2018-2029)
- 1.6.7 Middle East and Africa PD-L1 Biomarker Testing Market Size and Prospect (2018-2029)
2 Company Profiles
- 2.1 Agilent Technologies
- 2.1.1 Agilent Technologies Details
- 2.1.2 Agilent Technologies Major Business
- 2.1.3 Agilent Technologies PD-L1 Biomarker Testing Product and Solutions
- 2.1.4 Agilent Technologies PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
- 2.1.5 Agilent Technologies Recent Developments and Future Plans
- 2.2 Eli Lilly
- 2.2.1 Eli Lilly Details
- 2.2.2 Eli Lilly Major Business
- 2.2.3 Eli Lilly PD-L1 Biomarker Testing Product and Solutions
- 2.2.4 Eli Lilly PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
- 2.2.5 Eli Lilly Recent Developments and Future Plans
- 2.3 AstraZeneca
- 2.3.1 AstraZeneca Details
- 2.3.2 AstraZeneca Major Business
- 2.3.3 AstraZeneca PD-L1 Biomarker Testing Product and Solutions
- 2.3.4 AstraZeneca PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
- 2.3.5 AstraZeneca Recent Developments and Future Plans
- 2.4 Roche
- 2.4.1 Roche Details
- 2.4.2 Roche Major Business
- 2.4.3 Roche PD-L1 Biomarker Testing Product and Solutions
- 2.4.4 Roche PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
- 2.4.5 Roche Recent Developments and Future Plans
- 2.5 Bristol-Myers Squibb
- 2.5.1 Bristol-Myers Squibb Details
- 2.5.2 Bristol-Myers Squibb Major Business
- 2.5.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Product and Solutions
- 2.5.4 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
- 2.5.5 Bristol-Myers Squibb Recent Developments and Future Plans
- 2.6 Merck
- 2.6.1 Merck Details
- 2.6.2 Merck Major Business
- 2.6.3 Merck PD-L1 Biomarker Testing Product and Solutions
- 2.6.4 Merck PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
- 2.6.5 Merck Recent Developments and Future Plans
- 2.7 Pfizer
- 2.7.1 Pfizer Details
- 2.7.2 Pfizer Major Business
- 2.7.3 Pfizer PD-L1 Biomarker Testing Product and Solutions
- 2.7.4 Pfizer PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
- 2.7.5 Pfizer Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global PD-L1 Biomarker Testing Revenue and Share by Players (2018-2023)
- 3.2 Market Share Analysis (2022)
- 3.2.1 Market Share of PD-L1 Biomarker Testing by Company Revenue
- 3.2.2 Top 3 PD-L1 Biomarker Testing Players Market Share in 2022
- 3.2.3 Top 6 PD-L1 Biomarker Testing Players Market Share in 2022
- 3.3 PD-L1 Biomarker Testing Market: Overall Company Footprint Analysis
- 3.3.1 PD-L1 Biomarker Testing Market: Region Footprint
- 3.3.2 PD-L1 Biomarker Testing Market: Company Product Type Footprint
- 3.3.3 PD-L1 Biomarker Testing Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global PD-L1 Biomarker Testing Consumption Value and Market Share by Type (2018-2023)
- 4.2 Global PD-L1 Biomarker Testing Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
- 5.1 Global PD-L1 Biomarker Testing Consumption Value Market Share by Application (2018-2023)
- 5.2 Global PD-L1 Biomarker Testing Market Forecast by Application (2024-2029)
6 North America
- 6.1 North America PD-L1 Biomarker Testing Consumption Value by Type (2018-2029)
- 6.2 North America PD-L1 Biomarker Testing Consumption Value by Application (2018-2029)
- 6.3 North America PD-L1 Biomarker Testing Market Size by Country
- 6.3.1 North America PD-L1 Biomarker Testing Consumption Value by Country (2018-2029)
- 6.3.2 United States PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
- 6.3.3 Canada PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
- 6.3.4 Mexico PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
7 Europe
- 7.1 Europe PD-L1 Biomarker Testing Consumption Value by Type (2018-2029)
- 7.2 Europe PD-L1 Biomarker Testing Consumption Value by Application (2018-2029)
- 7.3 Europe PD-L1 Biomarker Testing Market Size by Country
- 7.3.1 Europe PD-L1 Biomarker Testing Consumption Value by Country (2018-2029)
- 7.3.2 Germany PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
- 7.3.3 France PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
- 7.3.4 United Kingdom PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
- 7.3.5 Russia PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
- 7.3.6 Italy PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
8 Asia-Pacific
- 8.1 Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Type (2018-2029)
- 8.2 Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Application (2018-2029)
- 8.3 Asia-Pacific PD-L1 Biomarker Testing Market Size by Region
- 8.3.1 Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Region (2018-2029)
- 8.3.2 China PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
- 8.3.3 Japan PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
- 8.3.4 South Korea PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
- 8.3.5 India PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
- 8.3.6 Southeast Asia PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
- 8.3.7 Australia PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
9 South America
- 9.1 South America PD-L1 Biomarker Testing Consumption Value by Type (2018-2029)
- 9.2 South America PD-L1 Biomarker Testing Consumption Value by Application (2018-2029)
- 9.3 South America PD-L1 Biomarker Testing Market Size by Country
- 9.3.1 South America PD-L1 Biomarker Testing Consumption Value by Country (2018-2029)
- 9.3.2 Brazil PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
- 9.3.3 Argentina PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
10 Middle East & Africa
- 10.1 Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Type (2018-2029)
- 10.2 Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Application (2018-2029)
- 10.3 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country
- 10.3.1 Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Country (2018-2029)
- 10.3.2 Turkey PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
- 10.3.3 Saudi Arabia PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
- 10.3.4 UAE PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
11 Market Dynamics
- 11.1 PD-L1 Biomarker Testing Market Drivers
- 11.2 PD-L1 Biomarker Testing Market Restraints
- 11.3 PD-L1 Biomarker Testing Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
- 11.5 Influence of COVID-19 and Russia-Ukraine War
- 11.5.1 Influence of COVID-19
- 11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
- 12.1 PD-L1 Biomarker Testing Industry Chain
- 12.2 PD-L1 Biomarker Testing Upstream Analysis
- 12.3 PD-L1 Biomarker Testing Midstream Analysis
- 12.4 PD-L1 Biomarker Testing Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on PD-L1 Biomarker Testing. Industry analysis & Market Report on PD-L1 Biomarker Testing is a syndicated market report, published as Global PD-L1 Biomarker Testing Market 2023 by Company, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of PD-L1 Biomarker Testing market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
